<DOC>
	<DOCNO>NCT00174356</DOCNO>
	<brief_summary>The main purpose study evaluate overall safety maximum dose CI 1033 combination paclitaxel carboplatin patient NSCLC .</brief_summary>
	<brief_title>PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Canertinib dihydrochloride</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>At least one target lesion unidimensionally measurable define Response Evaluation Criteria Solid Tumors ( RECIST ; Appendix B.2 ) previously irradiate ; tumor express least one member erbB family receptor ( determined immunohistochemical evaluation Sponsordesignated core laboratory ) Prior chemotherapy , biologic therapy , immunotherapy , treatment Herceptin , treatment investigational agent ( include CI 1033 ) ; hormonal therapy within 28 day prior baseline disease assessment ( exclude possibility hormonewithdrawal response ) ; prior definitive radiation therapy primary cancer site ; yet recover acute effect surgery palliative radiotherapy ; brain metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2006</verification_date>
</DOC>